ACECLIDINE SALICYLATE

Details

Stereochemistry	RACEMIC
Molecular Formula	C9H15NO2.C7H6O3
Molecular Weight	307.3416
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)C1=CC=CC=C1O.CC(=O)OC2CN3CCC2CC3

InChI

InChIKey=RGVBDFIRGIDMNP-UHFFFAOYSA-N

InChI=1S/C9H15NO2.C7H6O3/c1-7(11)12-9-6-10-4-2-8(9)3-5-10;8-6-4-2-1-3-5(6)7(9)10/h8-9H,2-6H2,1H3;1-4,8H,(H,9,10)

HIDE SMILES / InChI

Molecular Formula	C9H15NO2
Molecular Weight	169.2209
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Molecular Formula	C7H6O3
Molecular Weight	138.1207
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10411607
Curator's Comment: Description was created using several sources including: https://www.ncbi.nlm.nih.gov/pubmed/16229863 | https://www.ncbi.nlm.nih.gov/pubmed/12579779 | https://www.ncbi.nlm.nih.gov/pubmed/10845594

Aceclidine is a parasympathomimetic agent used in the treatment of open-angle glaucoma as topical eye drop solution. It is as a muscarinic acetylcholine receptor agonist with weak anticholinesterase activity. Acting directly on the motor end-plate (cholinergic nerve endings) it decreases intraocular pressure and mediates the contraction of iris muscle. Aceclidine increased outflow facility in human eyes in vitro by a direct stimulation of the outflow tissues in the absence of an intact ciliary muscle. This effect was biphasic, occurring at concentrations of 10 uM and lower with no effect at higher concentrations. Passed numerous clinical trials in Russia, France, Italy and other countries and was widely used in Europe but never been in clinical use in USA.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Muscarinic acetylcholine receptor M2 121 Target ID: CHEMBL211 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9715440	Agonist 2752	17.0 µM [EC50]
Muscarinic acetylcholine receptor M3 160 Target ID: CHEMBL245 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9715440	Agonist 2752
Muscarinic acetylcholine receptor M4 87 Target ID: CHEMBL1821 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9715440	Agonist 2752

Conditions

Condition	Modality	Targets	Highest Phase	Product
Glaucoma 57 Sources: https://www.drugs.com/international/aceclidine.html (2010) Medical Treatment of Glaucoma, page 33, retrieved from https://books.google.ru/books?id=-S9MdkiLttUC	Primary		Approved 8583	Glaunorm Approved Use Glaucoma, in its different clinical forms Launch Date 1969

Doses

Dose	Population	Adverse events
0.032 % 2 times / day multiple, topical Studied dose Dose: 0.032 %, 2 times / day Route: topical Route: multiple Dose: 0.032 %, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/16246781/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/16246781/	Sources: https://pubmed.ncbi.nlm.nih.gov/16246781/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inducer 1087			inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP19A1 429	P-gp 2052

Drug as perpetrator

Target	Modality	Activity	Metabolite	Clinical evidence
CYP19A1 430	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/1979#section=BioAssay-Results Page: 98.0	no
CYP3A4 2633	inducer 1966 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/1979#section=BioAssay-Results Page: 100.0	no

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 2052	substrate 4014 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/1979#section=BioAssay-Results Page: 99 \| 102	no

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/1979#section=BioAssay-Results Page: 48.0

PubMed

Title	Date	PubMed
Effectiveness of daily use of brimonidine as antimydriatic agent.	2009-10	19781497
Role of cholinergic and cytokine regulation of T cell function in stimulation and inhibition of immune reactions in intoxication by organophosphorus compounds in different doses.	2009-09	20396698
Aceclidine, brimonidine tartrate, and dapiprazole: comparison of miotic effect and tolerability under different lighting conditions.	2009-01	19101423
[The role of M-cholinoreceptors in the regulation of Th1 and Th2 lymphocyte functions].	2008-05-21	18488908
Aceclidine and pilocarpine interact differently with muscarinic receptor in isolated rabbit iris muscle.	2006-02-28	16229863
Pharmacological management of night vision disturbances after refractive surgery Results of a randomized clinical trial.	2005-09	16246781
Correlation between pK(a) and reactivity of quinuclidine-based catalysts in the Baylis-Hillman reaction: discovery of quinuclidine as optimum catalyst leading to substantial enhancement of scope.	2003-02-07	12558387
[The selectivity of the action of muscarinic agonists in vivo].	1994-03-01	8205054

Patents

Sample Use Guides

In Vivo Use Guide

Instill 2 drops of Glaunorm (2% aceclidine hydrochloride solution) into the conjunctival sac every 8 hours following the doctor's prescription

Route of Administration: Topical

In Vitro Use Guide

Human eyes were dissected and perfused. A steady state baseline facility was established for 90 minutes, after which up to four sequential concentrations ranging from 1 nM to 10 mM of aceclidine, were added to the perfusion medium. Outflow facility increased from baseline facility in eyes treated with aceclidine at lower concentrations (1 nM to 1 uM) but remained unchanged at higher concentrations.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:58:01 GMT 2025` Edited by `admin` on `Mon Mar 31 17:58:01 GMT 2025`
Record UNII	MCC2GG434J
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SALICYLIC ACID, COMPD. WITH 3-QUINUCLIDINOL ACETATE

Preferred Name

English

ACECLIDINE SALICYLATE

Common Name

English

2-HYDROXYBENZOIC ACID - 1-AZABICYCLO(2.2.2)OCT-3-YL ACETATE (1:1)

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C47796